Login
$XBIO
$1.49 -$0.17 (10.24%) Close

Company Executives

Officer Age 2024 pay Source
James Parslow
Interim Chief Executive Officer, Chief Financial Officer and Corporate Secretary
60 $481,168

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
6
serving now
Independent
4 of 4
stated in the proxy; 2 not stated
Average tenure
6.0 years
from year joined
CEO also chairs the board
No
Dmitry Genkin
Director Age On board Independent Committees Other public boards 2024 pay Source
Dmitry Genkin
56 2023
2 years
Not stated None stated None stated Not stated
Grigory Borisenko
56 2019
6 years
Independent
Audit Committee
None stated Not stated
Firdaus Jal Dastoor
72 2014
11 years
Independent None stated None stated $51,721
Roger Kornberg
78 2016
9 years
Independent None stated Cocrystal Pharma, Inc. Not stated
Moshe Mizrahy
72 2023
2 years
Not stated None stated InMode Ltd. Not stated
Alexey Vinogradov
55 2019
6 years
Independent None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

5 disclosed in the proxy filed Oct 31, 2025
PJSC Pharmsynthez
Amount not stated
November 2009

Collaborative research and development license agreement under which the Company granted Pharmsynthez an exclusive license to develop and commercialize six product candidates based on PolyXen and ImuXen technology in certain territories

SynBio LLC
Amount not stated
August 2011

Stock subscription and collaborative development agreement (Co-Development Agreement) granting exclusive licenses in SynBio Market and outside it; assigned to Pharmsynthez effective December 20, 2021

PJSC Pharmsynthez
Up to $500,000
fourth quarter of 2019

Loan agreement under which the Company advanced Pharmsynthez up to $500,000 at 10% interest, guaranteed by its subsidiaries and secured by Company stock; repaid May 2023

PeriNess Ltd.
Director Dr. Dmitry Genkin is a significant shareholder of PeriNess; director Mr. Moshe Mizrahy is a majority shareholder and director of PeriNess
Approximately $0.3 million
fourth quarter of 2024

Clinical trial services agreement to advance the systemic DNase I technology program in Israeli medical centers

Dr. Dmitry Genkin
Chairman of our Board of Directors
Approximately $0.3 million
nine months ended September 30, 2025

Consulting agreement, effective January 1, 2025, for consulting services to the DNase-based oncology program

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support